Synlogic, INC 8-K filings

Caldera Therapeutics and Synlogic are merging in an all-stock transaction, with Caldera to operate as the combined entity and seeking Nasdaq listing, supported by a $278 million private placement.

Synlogic, Inc. has withdrawn its Nasdaq listing appeal and will delist, planning to trade on the OTCQB Venture Market after being deemed a public shell.

Synlogic, Inc. announced its decision to withdraw its request for a Nasdaq hearing, leading to its delisting and a planned transition to OTC Markets Group.

Synlogic, Inc. stockholders approved a new 2025 Equity Incentive Plan, authorizing 1,000,000 shares plus potential additions, and reelected directors at their annual meeting.

Synlogic, Inc. received a notice from Nasdaq indicating its belief that the company is a public shell, initiating potential delisting proceedings.

Michael Heffernan resigned from Synlogic's board of directors and associated committees, effective immediately, with no reported disagreements with the company.

Nick Leschly resigned from Synlogic's board of directors and compensation committee, effective January 10, 2025.

Synlogic, Inc. has announced the departure of its Principal Executive Officer, Antoine Awad, effective December 31, 2024, and the appointment of Mary Beth Dooley as the new Principal Executive Officer and Principal Financial Officer, effective January 1, 2025.

Synlogic, Inc. held its annual meeting on December 4, 2024, where a director was re-elected, executive compensation was approved in an advisory vote, and the company's auditor was ratified.

Synlogic announced its Q3 2024 financial results, revealing a significant reduction in net loss and the exploration of strategic options to maximize shareholder value.

Synlogic announced its Q2 2024 financial results, reporting a net income of $2.0 million due to restructuring gains, while also exploring strategic options to maximize shareholder value.

Synlogic announced its Q1 2024 financial results, including a net loss of $31.6 million, and is exploring strategic options to maximize shareholder value.

Synlogic, Inc. has appointed James Flynn to its Board of Directors, while three other directors, Mike Burgess, Lisa Kelly-Croswell, and Patricia N. Hurter, have resigned, all effective March 20, 2024.

Synlogic announced its full year 2023 financial results, highlighted by increased revenue from a Roche collaboration, but also disclosed the discontinuation of a key clinical trial and a strategic review.

Synlogic, Inc. has announced the departures of its CEO, Aoife Brennan, and COO, Antoine Awad, with separation agreements detailing payments and benefits.

Synlogic, Inc. has adopted a shareholder rights plan to protect against unsolicited takeover attempts and to ensure shareholders receive fair value for their investment.

Synlogic has decided to discontinue its Synpheny-3 study for phenylketonuria, leading to a strategic review, a 90% workforce reduction, and the departure of its CEO.